Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3454-3458

  Salleras, L ^a,b   Navas, E ^c   Dominguez A ^a,c   Ibanez D ^c   Prat, A ^a,b   Garrido, P ^a   Asenjo, M A ^a   Torner, N ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Generalitat of Catalonia ^*  (Spain)

Author keywords

Children; Cost benefit; Cost effectiveness; Effectiveness; Inactivated virosomal influenza vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; INFLUENZA VACCINE; VIROSOME VACCINE;

ABSENTEEISM; ADOLESCENT; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MEDICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPAIN; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FAMILY; HUMANS; INFLUENZA VACCINES; PHYSICAL EXAMINATION; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VACCINES, VIROSOME;

EID: 67349086036     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.053     Document Type: Article

References (30)

1. Muñoz F.M. The impact of influenza in children. Semin Pediatr Infect Dis 13 (2002) 72-78
2. Heikkinen T., Silvennoinen H., Peltola V., Ziegler T., Vainionpaa R., Vuorinen T., et al. Burden of influenza in children in the community. J Infect Dis 190 (2004) 1369-1373
3. CDC Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51 RR-3 (2002) 1-34
4. CDC Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 RR-10 (2006) 1-42
5. CDC. Recommended immunization schedules for persons aged 0-18 years-United States, 2008. MMWR 57 (2008) Q1-Q4
6. Neuzil K.M., Jackson L.A., Nelson J., Klimov A., Cox N., Bridges C.B., et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194 (2006) 1032-1039
7. Zangwill K.M., and Belshe R.B. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 23 (2004) 189-200
8. Jefferson T., Smith S., Demicheli V., Harnden A., Rivetti A., and Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365 (2005) 773-780
9. Negri E., Colombo C., Giordano L., Groth N., Apolone G., and La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 23 (2005) 2851-2861
10. Salleras L., Dominguez A., Pumarola T., Prat A., Marcos M.A., Garrido P., et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 24 (2006) 6638-6642
11. Haddix A.C., Teutsch S.M., Shaffer P.A., and Duñet D.O. Prevention effectiveness: a guide to decision analysis and economic evaluation (1996), Oxford University Press, New York pp. 12-26
12. Edwards K.M., and Griffin M.R. Influenza paediatric vaccination: can it be accomplished?. J Infect Dis 194 (2006) 1027-1029
13. Pisu M., Meltzer M.I., Hurwitz E.S., and Haber M. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study. Pharmacoeconomics 23 (2005) 55-67
14. Rudenko L.G., Slepushkin A.N., Monto A.S., Kendal A.P., Grigorieva E.P., Burtseva E.P., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 168 (1993) 881-887
15. Esposito S., Marchisio P., Cavagna R., Gironi S., Bosis S., Lambertini L., et al. Effectiveness of influenza paediatric vaccination with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21 (2003) 3162-3168
16. Gruber W.C., Taber L.H., Glezen W.P., Clover R.D., Abell T.D., Demmler R.W., et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 144 (1990) 595-600
17. Clover R.D., Crawford S., Glezen W.P., Taber L.H., Matson C.C., and Couch R.B. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 163 (1991) 300-304
18. Hurwitz E.S., Haber M., Chang A., Shope T., Teo S., Ginsberg M., et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284 (2000) 1677-1682
19. Colombo C., Argiolas L., La Vecchia C., Negri E., Meloni G., and Meloni T. Influenza vaccine in healthy preschool children. Rev Epidemiol Sante Publique 49 (2001) 157-162
20. Principi N., Esposito S., Marchisio P., Gasparini R., and Crovari P. Socioeconomic impact of influenza in healthy children and their families. Pediatr Infect Dis J 22 Suppl. 10 (2003) S207-S210
21. Jordan R., Connock M., Albon E., Fry-Smith A., Olowokure B., Hawker J., et al. Universal paediatric vaccination against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 24 (2006) 1047-1062
22. Esposito S., Marchisio P., Bosis S., Lambertini L., Claut L., Faelli N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24 (2006) 629-635
23. Cohen G.M., and Nettleman M.D. Economic impact of influenza vaccination in preschool children. Paediatrics 106 (2000) 973-976
24. White T., Lavoie S., and Nettleman M.D. Potential cost savings attributable to influenza vaccination of school-aged children. Paediatrics 103 (1999) e73
25. Salo H., Kilpi T., Sintonen H., Linna M., Peltola V., and Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 24 (2006) 4934-4941
26. Marchetti M., Kuhnel U.M., Colombo G.L., Esposito S., and Principi N. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 3 (2007) 14-22
27. Navas E., Salleras L., Domínguez A., Ibáñez D., Prat A., Sentís J., et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 2007 25 (2007) 3233-3239
28. Skowronski D.M., Woolcott J.C., Tweed S.A., Brunham R.C., and Marra F. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine 24 (2006) 4222-4232
29. Meltzer M.I., Neuzil K.M., Griffin M.R., and Fukuda K. An economic analysis of annual influenza paediatric vaccination. Vaccine 23 (2005) 1004-1014
30. Imai K., and Zhang P. Integrating economic analysis into clinical trials. Lancet 365 (2005) 1749-1750